1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester NEW

Product introduce: 1-（4-Methoxypheny1)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-

Tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid ethyl ester is an intermediate for preparing apixaban, which is an antithrombotic drug. It is a direct inhibitor of factor Xa jointly developed by Bristol-Myers Squibb and Pfizer. It was approved for marketing in the European Union in March 2011 and approved for marketing in the United States by the FDA in December 2012.